Disproven
S1P receptor modulation (lymphocyte trafficking): slow disability worsening in primary progressive MS
primary progressive MS · S1P receptor modulation (lymphocyte trafficking)
Placebo-controlled phase 3 trials missed their main goal, and none succeeded. This applies to this patient group only.
- Trials
- 2
- Running now
- 1
- Controlled phase 2/3 trials
- 1
- People in controlled trials
- 970
Deciding trials (phase 3): 0 met, 1 did not.
Other linked trials: 1
Dose comparisons, trials against another medicine, add-on trials, phase 1 and uncontrolled studies. They are listed below but do not set the status.
Trials
Phase 3 · 2008 · Placebo-controlled · MSFT-NCT00731692
Other linked trials: 1
These linked trials do not set the status.
- SIPO20Ongoing
Phase 4 · 2022 · Not randomised
The deciding phase and counts come from the Trial Bank’s fixed rules.
Lab evidence
Lab studies in animals or cells. Results in animals often do not hold in people, and these studies never change the status of an idea.
Loading lab studies…
Loading reviews and guidelines…
History
- 2026-10-28Trials: 1 → 2
- 2026-10-27First listed as Disproven
Related hypotheses
- S1P receptor modulation (lymphocyte trafficking): slow disability worsening in relapsing MS
- S1P receptor modulation (lymphocyte trafficking): slow disability worsening in relapsing and progressive MS
- S1P receptor modulation (lymphocyte trafficking): slow disability worsening in secondary progressive MS
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error